The Limits of Biomarkers

Hepatitis C in Renal Disease, Hemodialysis and Transplantation

This flow develops the theme that laboratory measurements can reveal disease while also misleading clinicians in dialysis and transplantation.

increasing

Bearing strength in each event

decreasing

Quiet Enzymes Quiet Enzymes from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Quiet Enzymes A misleading normality Aminotransferase levels are often lower in dialysis patients, even when HCV viremia persists.

Quiet Enzymes from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Quiet Enzymes A misleading normality Aminotransferase levels are often lower in dialysis patients, even when HCV viremia persists.

Quiet Enzymes A misleading normality Aminotransferase levels are often lower in dialysis patients, even when HCV viremia persists. Normal-range values may therefore conceal active liver injury. Recalibrating interpretation Clinicians must interpret laboratory data within renal context. A number loses meaning when the physiology that produced it has changed.

RNA Confirmation RNA Confirmation from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". RNA Confirmation Infection versus memory Anti-HCV antibodies show exposure but cannot distinguish resolved from active infection.

RNA Confirmation from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". RNA Confirmation Infection versus memory Anti-HCV antibodies show exposure but cannot distinguish resolved from active infection.

RNA Confirmation Infection versus memory Anti-HCV antibodies show exposure but cannot distinguish resolved from active infection. HCV RNA testing establishes whether the virus remains present. A decisive distinction Treatment, transplant eligibility, and donor allocation depend on this difference. Molecular testing converts an ambiguous history into a current biological state.

Biopsy as Ground Truth Biopsy as Ground Truth from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Biopsy as Ground Truth Tissue over appearance Liver biopsy stages fibrosis when enzymes and symptoms are unreliable.

Biopsy as Ground Truth from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Biopsy as Ground Truth Tissue over appearance Liver biopsy stages fibrosis when enzymes and symptoms are unreliable.

Biopsy as Ground Truth Tissue over appearance Liver biopsy stages fibrosis when enzymes and symptoms are unreliable. Kidney biopsy distinguishes HCV-related immune-complex injury from rejection and transplant glomerulopathy. Invasive clarity Biopsy carries bleeding, anxiety, and sampling limitations, yet it often provides the information on which major decisions depend. The theme is not that biomarkers are useless, but that they require anatomical confirmation.

during chronic Hemodialysis

after positive antibody testing

during pretransplant assessment or graft dysfunction